|
|
|
"Meningococcal disease is a devastating illness that can result in rapid death or have long-lasting repercussions for survivors and their families," said Andrin Oswald, CEO of Novartis Vaccines and Diagnostics. Through industry-leading scientific expertise, the company is focused on extending critical meningococcal vaccines research.
Five serogroups cause the majority of meningococcal disease worldwide: A, B, C, W-135 and Y[1]. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected.
About Novartis
Novartis Vaccines and Diagnostics is a division of Novartis focused on the development of preventive treatments. AEOL 10150 is under development as a countermeasure for nuclear and radiological exposure and as a protective agent in cancer patients receiving radiation therapy.D. In total 60 animals were exposed to 15 gy single dose radiation to the whole thorax. Untreated mice experienced a steady decline in body weight over the six weeks, while treated animals experienced weight gain that was just slightly less than that seen in the controls (animals not receiving radiation).
About Aeolus Pharmaceuticals
Aeolus is developing a variety of therapeutic agents based on its proprietary small molecule catalytic antioxidants, with AEOL 10150 being the first to enter human clinical evaluation.
buspar amitriptyline with xanax combination addictive diazepam valium and alprazolam xanax buy cg site xanax can xanax cause hair loss discontinuing xanax er no prescription generic xanax pharmacys online xanax what kind of drug is xanax
meningitidis). For more information, please visit www.
References [1. Meningococcal meningitis Fact sheet.D. AEOL 10150 is under development as a countermeasure for nuclear and radiological exposure and as a protective agent in cancer patients receiving radiation therapy.”
The study protocol called for four groups of animals, two of which would be studied for 6 weeks to look at the acute effects of Lung ARS and the potential efficacy of AEOL 10150 as a countermeasure, and two which would be studied for six months to look at the chronic effects of Lung ARS and the potential efficacy of AEOL 10150 as a countermeasure. Untreated mice experienced a steady decline in body weight over the six weeks, while treated animals experienced weight gain that was just slightly less than that seen in the controls (animals not receiving radiation). Doses in the range of 5 to 10 mg/kg/d showed a more potent effect including more significant mitigation as assessed by histopathology and immunohistochemistry.
“AEOL 10150 continues to demonstrate significant, protective effects when administered after exposure to radiation,” stated John L.
|
|
No News has been posted yet
|
|
|
Forgotten your password? Request a new one here.
|
 Guests Online: 1
No Members Online
Registered Members: 1
Unactivated Members: 0
Newest Member: Owen Electrical
|
|
v6.01.1 © 2003-2005